VistaGen Therapeutics Company Presentation

ƒ Odorless, synthetic neuroactive nasal spray ƒ Fast-acting (within 15 minutes) ƒ Non-systemic ƒ Exceptional safety in all clinical studies to date ƒ Highly statistically significant Phase 2 study (p=0.002) ƒ FDA consensus on Phase 3 studies to mirror Phase 2 ƒ FDA Fast Track designation granted Neuroactive Nasal Spray Acute Treatment of Anxiety for Adults with Social Anxiety Disorder Potential to be the first FDA-approved fast-acting acute treatment of anxiety for adults with Social Anxiety Disorder LOOKING BEYOND THE STANDARD OF CARE FOR ANXIETY, DEPRESSION AND OTHER CNS DISORDERS